What the GLP-1 weight-regain trial found
A pilot randomised trial published in 2026 in Obesity Science & Practice suggests that structured support may reduce early weight regain in adults stopping GLP-1 treatment. According to Medical Xpress, the study assigned 39 adults who had previously lost weight with these medicines to usual care, a digital wellness app or medically tailored meals, following them for four months.
Support began when participants stopped medication. Over the follow-up period, estimated weight gain was 10.75% in the usual-care group, 3.60% in the app group and 3.58% in the tailored-meals group.
Those figures represent a difference of about seven percentage points between usual care and either support option. The estimated percentage weight gain was roughly two-thirds lower with support, but neither intervention prevented regain altogether. These percentages describe changes in body weight, not the proportion of previous weight loss that participants regained.
The app and meal groups had very similar estimates. That does not establish that the two approaches are equally effective: a small pilot trial cannot reliably settle such a comparison. Medical Xpress's account does not provide confidence intervals or a statistical significance result for the weight differences, limiting how precisely readers can judge them.
Why weight can return after GLP-1 treatment
GLP-1 receptor agonists act on pathways involved in appetite and blood glucose regulation. Medicines in this class include semaglutide, sold for weight management as Wegovy. Once treatment stops, its appetite-regulating effects do not continue indefinitely, helping to explain why maintaining the lower weight can become difficult.
The source identifies cost, insurance restrictions, side effects and personal preference among the reasons people discontinue treatment. Those are general reasons for stopping; the report does not specify why the 39 participants ended their medication.
This study concerns adults who had already lost weight, rather than people starting treatment. Its findings should not be extended to children, whose prescribing considerations are different, as covered in our report on WHO advice against weight-loss injections for under-10s.
Nor does the report identify the medicines, app or meal provider used. It therefore offers no basis for endorsing a particular commercial product. Questions about how treatments are promoted, including ASA scrutiny of weight-loss drug adverts, are distinct from whether a specific form of support works after treatment ends.
What the Tufts researcher said about support
Kelseanna Hollis-Hansen, the corresponding author at Tufts University Food is Medicine Institute, said: “People invest significant time and effort in improving their health and achieving weight loss.”
She called for evidence-based ways to help people preserve their progress when they discontinue medication. The trial addresses that practical question, but its questionnaire findings were less clear-cut than the weight estimates: diet quality, perceived health, adherence and satisfaction did not differ significantly between groups. Some estimates leaned towards the app, without establishing a reliable advantage.
What larger GLP-1 follow-up studies need to establish
The central unanswered question is whether the apparent benefit lasts beyond four months. The study cannot show whether weight gain subsequently slows, continues or converges across the groups.
Larger trials would also be needed to estimate the size of any benefit more reliably and establish who is most likely to benefit. Random allocation strengthens the comparison, but with only 39 participants, chance differences between groups remain an important concern.
The source does not announce a follow-up trial or a timetable for further results. For patients considering stopping treatment, these findings are a reason to discuss ongoing support with their prescriber, not evidence that an app or meal service can replace medication.
